Consensus IDEXX Laboratories, Inc.

Stocks

IDXX

US45168D1046

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 16:00:00 2026-10-01 EDT			5-day change	1st Jan Change
517.75 ^USD	-0.85%		+0.85%	-23.47%

09-30	IDEXX Laboratories Acquires Veterinary AI Platform CoVetAI	MT
09-17	Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Amid Economic Data, Fed Rate Hike	MT

Evolution of the Average Target: IDEXX Laboratories, Inc.

Evolution of the Target Price: IDEXX Laboratories, Inc.

Changes in Analyst Recommendations: IDEXX Laboratories, Inc.

9ce3a70c88dd18121a72595.tu6F_FeYUUvsB1jC5Bnf_A_Mj1Lvy1FBEV0Y-jryW4g._tvfxQGsM3-ZT2603VuIt0L7vwqnhiIrYA5yu3uqOObyl72xEtxpIr5yDQ~2fde2d5daab73ab6fedaeb1e990663b3

Analysts' recommendations: IDEXX Laboratories, Inc.

08-11	Barclays Adjusts Price Target on IDEXX Laboratories to $710 From $800, Keeps Overweight Rating	MT
08-05	Jefferies Adjusts Price Target on IDEXX Laboratories to $795 From $792	MT
08-05	Citigroup Adjusts Price Target on IDEXX Laboratories to $670 From $650	MT
08-05	UBS Adjusts Price Target on IDEXX Laboratories to $670 From $620, Maintains Neutral Rating	MT
07-27	Elanco Seems Best-Positioned Into Q2 Print Among Animal Health Stocks, UBS Says	MT
07-27	UBS Cuts IDEXX Laboratories Price Target to $620 From $640, Maintains Neutral Rating	MT
07-13	Leerink Partners Adjusts IDEXX Laboratories Price Target to $715 From $725, Maintains Outperform Rating	MT
05-06	Rothschild & Co Redburn Adjusts Price Target on IDEXX Laboratories to $665 From $655	MT
05-06	Jefferies Adjusts Price Target on IDEXX Laboratories to $792 From $785	MT
04-28	UBS Adjusts Price Target on IDEXX Laboratories to $640 From $730, Maintains Neutral Rating	MT
04-27	Jefferies Adjusts Price Target on IDEXX Laboratories to $785 From $820, Maintains Buy Rating	MT
04-15	Citigroup Initiates IDEXX Laboratories at Neutral With $650 Price Target	MT
04-14	Leerink Partners Adjusts IDEXX Laboratories PT to $725 From $760, Maintains Outperform Rating	MT
03-31	Stifel Nicolaus Adjusts IDEXX Laboratories PT to $675 From $775, Maintains Buy Rating	MT
02-09	Piper Sandler Adjusts Price Target on IDEXX Laboratories to $750 From $775, Maintains Neutral Rating	MT
02-05	Barclays Adjusts Price Target on IDEXX Laboratories to $800 From $850, Maintains Overweight Rating	MT
02-04	Barclays Lowers Price Target on IDEXX Laboratories to $800 From $850	MT
02-03	Jefferies Adjusts Price Target on IDEXX Laboratories to $820 From $830	MT
02-03	UBS Adjusts IDEXX Laboratories PT to $730 From $750	MT
02-03	Leerink Partners Adjusts Price Target on IDEXX Laboratories to $760 From $785	MT
02-03	BTIG Adjusts Price Target on IDEXX Laboratories to $800 From $830	MT
02-03	Rothschild & Co Redburn Adjusts Price Target on IDEXX Laboratories to $655 From $700	MT
12-09	Barclays Initiates IDEXX Laboratories With Overweight Rating, $850 Price Target	MT
11-10	Piper Sandler Adjusts Price Target on IDEXX Laboratories to $775 From $700	MT
11-04	UBS Adjusts Price Target on IDEXX Laboratories to $750 From $710, Maintains Neutral Rating	MT

More recommendations

Veterinary Medical Equipment & Supplies

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	IDEXX LABORATORIES, INC.					+35.46%
	ABBOTT LABORATORIES					+24.38%
	MEDTRONIC PLC					+21.28%
	STRYKER CORPORATION					+34.74%
	ESSILORLUXOTTICA					+60.86%
	CENCORA, INC.					+19.2%
	HOYA CORPORATION					+23.82%
	BECTON, DICKINSON AND COMPANY					+9.88%
	DEXCOM, INC.					+10.26%
	ALCON INC.					+43.49%
	Average					+28.34%
	Weighted average by Cap.					+28.56%